(INVA) Innoviva, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(INVA) Innoviva, Inc. Complete Analysis Pack
Innoviva's Biotech & Royalty Model, in One Clear Business Model Canvas
Discover how Innoviva, Inc. creates value through its focused biotech and royalty-driven business model. This concise Business Model Canvas highlights the key partnerships, revenue streams, and strategic priorities behind the company’s performance. Get the full version for a deeper, ready-to-use analysis.
Partnerships
Glaxo Group Limited agreement
Innoviva’s Glaxo Group Limited agreement is a core royalty engine for daily LABA-based COPD and asthma drugs, including the Ellipta respiratory franchise. GSK reported Trelegy Ellipta sales of about £3.4 billion in 2024, which helps show why this tie-up remains central to Innoviva’s respiratory portfolio.
Sarissa Capital Management LP alliance
Innoviva’s alliance with Sarissa Capital Management LP is a named strategic partnership that supports capital-allocation and capital-markets goals. In 2025, Innoviva kept a market value in the low billions, so this relationship matters for investor communication and strategy execution.
Respiratory commercialization collaboration
In FY2025, Innoviva kept its inhaled-respiratory model partner-led, using long-term commercialization ties to reach global markets without funding a full in-house sales force. This setup fits a royalty-heavy business: third-party partners handle development, approval, and launch, while Innoviva stays asset-light and focused on recurring economics.
Manufacturing and supply partners
Innoviva, Inc. relies on external manufacturing and supply partners because combination inhalers need tight control of formulation, device assembly, and cold-chain-free global distribution. That setup helps keep quality and availability steady across respiratory markets, where even small supply slips can hit patients fast.
- Specialized inhaler production
- Stable global supply
- Quality control at scale
For global respiratory medicines, these partners reduce execution risk and support consistent product access across regions.
Healthcare ecosystem partners
Physicians, hospitals, pharmacies, and payers shape access to Innoviva, Inc.'s inhaled therapies by deciding what gets prescribed, stocked, and reimbursed. Their formulary and reimbursement calls can speed or block uptake, so these partners sit at the center of product demand and patient access.
- Prescribing drives therapy starts
- Hospitals shape inpatient access
- Pharmacies affect fill rates
- Payers set reimbursement access
Innoviva’s Royalty Engine Runs on GSK and Key Partners
Innoviva, Inc. depends on Glaxo Group Limited for the core Ellipta royalty stream, and GSK reported about £3.4 billion in Trelegy Ellipta sales in 2024, underscoring that link. It also works with Sarissa Capital Management LP on capital allocation and investor strategy, while outside manufacturers and supply partners keep inhaler production and global delivery asset-light.
| Partner | Role | Latest signal |
|---|---|---|
| Glaxo Group Limited | Royalty engine | Trelegy sales £3.4B |
| Sarissa Capital Management LP | Capital strategy | Active in 2025 |
| Supply partners | Manufacturing, delivery | Asset-light model |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Innoviva, Inc. that maps its pharma royalties, partnerships, and value creation.
Customizable Excel Spreadsheet
Quickly maps Innoviva, Inc.’s pain points and value drivers in one clear, editable business snapshot.
Reference Sources
Provides a credible source trail for Innoviva, Inc. that supports faster, more confident decision-making.
Activities
Therapy development
Innoviva, Inc. centers therapy development on respiratory disease, with LABA-based combination treatments built for COPD and asthma. Its respiratory franchise generated $313.0 million in net product sales in 2024, showing the commercial pull behind its development work.
Commercialization of Ellipta products
Innoviva, Inc. supports global commercialization of RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA, the three Ellipta brands that anchor its royalty model. In 2025, this once-daily inhaled-therapy franchise remained the core value driver, with TRELEGY ELLIPTA alone reported by GSK as a multibillion-dollar product.
Alliance management
Innoviva’s alliance management centers on 2 key relationships: Glaxo Group Limited and Sarissa Capital Management LP. Ongoing contract execution and partner coordination are core workstreams, and these alliances remain operationally important because they shape cash flows, governance, and execution across the business.
Portfolio and brand management
Innoviva manages a respiratory portfolio centered on LABA, ICS, and LAMA combinations, using brand support to keep COPD and asthma products positioned well. In its latest filed results, Innoviva reported $71.4 million in 2023 net revenues from joint ventures and royalty-related income, underscoring the value of lifecycle and market support.
- Protects COPD and asthma brand share
- Supports product lifecycle extensions
- Drives portfolio revenue through stewardship
Regulatory and compliance work
Innoviva, Inc. has to keep strict regulatory and compliance work in place so its pharmaceutical assets can stay approved, labeled correctly, and sold across major markets. In 2025, this matters even more for global treatments, where FDA and EMA rules can change launch timing, safety language, and market access.
- Support product approvals and label updates
- Track changing FDA and EMA rules
- Keep global compliance in place
Innoviva Defends Its Respiratory Cash Engine
Innoviva, Inc.’s key work is managing and defending its respiratory franchise, especially RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. The company also runs alliance management, regulatory tracking, and lifecycle support to protect royalty cash flows and market access.
| Key activity | 2025/2024 data |
|---|---|
| Respiratory franchise sales | $313.0 million net product sales in 2024 |
| Royalty-related income | $71.4 million in 2023 |
Full Version Awaits
Business Model Canvas
The Innoviva, Inc. Business Model Canvas previewed here is the exact document you’ll receive after purchase, not a sample or mockup. What you see on this page is a direct snapshot of the final file, with the same structure, content, and formatting. Once you buy, you’ll get full access to this same ready-to-use document instantly.
Resources
RELVAR/BREO ELLIPTA brand
In 2025, RELVAR/BREO ELLIPTA stayed one of Innoviva, Inc.’s main royalty assets, supporting recurring cash flow from GSK sales. It is a once-daily inhaled dual therapy that pairs vilanterol 25 mcg with fluticasone furoate 100/200 mcg, and it remains a core respiratory brand in asthma and COPD.
ANORO ELLIPTA brand
ANORO ELLIPTA combines umeclidinium bromide 62.5 mcg with vilanterol 25 mcg and sits in Innoviva, Inc.’s inhaled maintenance portfolio. It supports once-daily COPD control in a disease that affects about 390 million people worldwide.
TRELEGY ELLIPTA brand
TRELEGY ELLIPTA is Innoviva, Inc.'s flagship respiratory asset: a once-daily triple-therapy inhaler combining an ICS, a LAMA, and a LABA. GSK reported TRELEGY sales of about £3.5 billion in 2024, underscoring the brand’s scale and its value as a royalty-backed key resource for Innoviva, Inc.
Respiratory product agreements
Innoviva's agreement with Glaxo Group Limited is a core resource because it gives Innoviva contract rights to develop and commercialize LABA-based respiratory products, including royalty streams tied to GSK's marketed portfolio. In 2025, those rights remained the company's main economic asset and a key driver of cash flow.
That makes the GSK contract more than a license; it is the asset base behind Innoviva's respiratory business model. If the underlying products keep selling, the agreement keeps converting respiratory demand into recurring revenue.
- Core resource: GSK contract rights
- Supports LABA product commercialization
- Drives recurring royalty cash flow
Corporate base in Burlingame
Innoviva’s corporate base in Burlingame, California is its main operating hub, where management, finance, and strategic oversight sit together. The headquarters gives the company a central base for portfolio decisions, capital allocation, and corporate control, which matters for a company built around pharma royalties and investment holdings.
Burlingame, California headquarters
Supports management and finance
Main base for strategic oversight
Innoviva’s Royalty Engine: GSK Rights and TRELEGY Drive Cash Flow
Innoviva, Inc.'s key resources are its GSK contract rights and royalty assets tied to RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. TRELEGY alone delivered about £3.5 billion in GSK sales in 2024, showing the scale behind Innoviva, Inc.'s recurring cash flow.
| Resource | Role | Data |
|---|---|---|
| GSK rights | Royalty base | Main 2025 asset |
| TRELEGY | Flagship royalty | £3.5B sales, 2024 |
Value Propositions
Once-daily dosing
Innoviva, Inc.’s respiratory value proposition centers on once-daily inhaled therapies, including the 1-inhalation-a-day Trelegy Ellipta regimen. One daily dose can simplify maintenance treatment versus 2-3 daily doses, which helps patients stay on therapy and gives prescribers a cleaner, easier-to-follow option.
Combination respiratory therapy
Innoviva’s combination respiratory therapy spans LABA, ICS, and LAMA formats, including once-daily triple therapy like Trelegy Ellipta, so it targets multiple disease pathways in one regimen. In 2025, this broad mix helped support treatment across asthma and COPD, where step-up therapy is often needed.
COPD and asthma focus
Innoviva focuses on COPD and asthma, two huge respiratory markets with long-term treatment needs: COPD affects about 390 million people worldwide and asthma about 262 million, according to WHO. That chronic demand fits Innoviva’s collaboration model, which is built to share risk and monetize partnered respiratory therapies over time.
Triple-therapy option
TRELEGY ELLIPTA combines 3 drugs in 1 inhaler: an ICS, a LAMA, and a LABA. That gives eligible COPD and asthma patients a single, once-daily triple-therapy option, and it broadens Innoviva, Inc.’s clinical reach through royalty-linked exposure to a proven blockbuster brand.
- 3 classes, 1 inhaler
- Once-daily triple therapy
- Broader clinical coverage
- Royalty-linked value driver
Global respiratory access
Innoviva’s respiratory model is built for worldwide commercialization, so branded inhaled therapies can reach patients beyond a single market. Its access story is tied to global franchises like Trelegy Ellipta, which generated multi-billion-dollar annual sales in 2024, showing how one approved therapy can scale across regions and support broad access.
- Global reach beyond one market
- Supports branded inhaled therapy access
- Scales through partner commercialization
Innoviva’s 3-in-1 Inhaler Drives Simpler COPD and Asthma Care
Innoviva’s value proposition is simple: once-daily, multi-mechanism inhaled therapy for COPD and asthma, led by TRELEGY ELLIPTA’s 3-in-1 LABA/ICS/LAMA design. That lowers dosing burden, supports adherence, and gives partner-led commercialization a scalable royalty stream.
| Metric | Value |
|---|---|
| TRELEGY ELLIPTA | 1 inhaler, 1 dose daily |
| Drug classes | 3 |
| COPD patients worldwide | 390 million |
| Asthma patients worldwide | 262 million |
Customer Relationships
Long-term pharma agreements
Innoviva, Inc. builds customer relationships through multi-year pharma alliances that keep development, regulatory work, and commercialization tied together for years. Its model depends on continuity: in the latest reported year, royalty revenue stayed tied to long-running partner sales, including GSK’s Trelegy Ellipta, which generated about $3 billion in annual sales.
Partner-managed engagement
Innoviva, Inc. relies on partner-managed engagement, so most customer contact sits with commercial partners that handle market access, sales, and distribution. This is a B2B, contract-based setup that fits its royalty-led model and keeps direct customer touchpoints limited.
Clinical evidence support
Innoviva, Inc.’s respiratory products depend on clinical proof because COPD affects about 390 million people worldwide, and doctors and payers want evidence on outcomes and safety. That evidence helps drive prescriber trust, payer coverage, and repeat use, so clinical support stays central to customer relationships.
Regulatory and compliance trust
Pharma customers buy trust, so Innoviva’s regulatory and quality record must stay tight. Strong execution against FDA and other compliance rules lowers supply risk, protects product confidence, and supports long-term contracts with partners that expect zero drift in standards.
- Quality drives repeat pharma business.
- Compliance protects product confidence.
- Strong execution supports long ties.
Lifecycle support
Innoviva, Inc. keeps customer ties alive through lifecycle support for RELVAR/BREO, ANORO, and TRELEGY, because these respiratory brands need ongoing medical, payer, and prescriber support after launch. That matters: TRELEGY delivered $3.5 billion in GSK sales in 2024, so small shifts in access, education, or adherence can protect a very large revenue base.
Brand support extends post-launch demand.
Lifecycle management helps defend market relevance.
Ongoing support keeps relationships active.
Innoviva’s Pharma Partnerships Power $3.5B in TRELEGY Sales
Innoviva, Inc. keeps customer ties mostly through long-term pharma partners, so trust, compliance, and lifecycle support matter more than direct selling. Its relationship model is anchored by royalty-linked brands like TRELEGY, which reached $3.5 billion in GSK sales in 2024.
| Metric | Value |
|---|---|
| TRELEGY sales | $3.5B |
| Relationship type | Long-term B2B |
Channels
Partner commercialization channels
Innoviva uses a partner-led route to market, with Glaxo Group Limited as the core commercialization channel; this single collaboration supports development and sales reach without a large in-house commercial force. In its model, 1 major partner does most of the market access work, which keeps fixed selling costs low and ties revenue exposure to partner execution.
Healthcare provider channel
Physicians and specialists drive Innoviva, Inc.’s respiratory demand: in 2025, COPD affected about 16 million U.S. adults and asthma about 25 million, so prescribing behavior directly shapes product use. This healthcare provider channel is key because pulmonologists and primary care doctors decide therapy starts, refills, and switches for COPD and asthma.
Pharmacy distribution
Pharmacy distribution is the last-mile channel for Innoviva, Inc.'s inhaled medicines: once prescribed, they move through retail and specialty pharmacies so patients can start and refill treatment on time. This is standard pharma practice, and pharmacies still handle about 90% of U.S. outpatient prescriptions, so access after prescribing is a major part of demand capture.
Hospital and clinic access
Hospital and outpatient clinics shape maintenance inhaler uptake because formulary access and purchasing rules decide what gets started and refilled. For Innoviva, Inc., these institutional channels matter most where payer controls are tight; in 2025, hospital care accounted for about 30% of U.S. health spending, so procurement teams still drive a large share of drug access.
- Formulary status drives first use
- Procurement affects refill continuity
- Hospitals anchor institutional demand
Payer and formulary access
Payer and formulary access decides whether Innoviva, Inc.'s branded respiratory therapies get filled. In the U.S., the 3 largest pharmacy benefit managers handle about 80% of prescriptions, so coverage terms, rebates, and prior auth rules can make or break uptake.
- Access drives patient fills.
- PBMs shape formulary placement.
- Coverage is critical for respiratory brands.
Innoviva’s Partner-Led Model Targets a Massive COPD and Asthma Market
Innoviva, Inc. sells through a partner-led channel, with Glaxo Group Limited doing most market access work, so the company keeps a lean commercial model. Doctors, pharmacies, and payers then decide uptake: in 2025, about 16 million U.S. adults had COPD and 25 million had asthma, while the 3 largest PBMs controlled about 80% of prescriptions.
| Channel | 2025/2026 data |
|---|---|
| Partner | 1 core commercial ally |
| Physicians | 16M COPD; 25M asthma |
| PBMs | Top 3 manage 80% rx |
Customer Segments
COPD patients
COPD patients are Innoviva, Inc.’s core customer segment, because the portfolio is built around long-term COPD maintenance. This fits ANORO and TRELEGY, two once-daily inhaled therapies that serve a market where COPD affects about 16 million diagnosed U.S. adults and roughly 392 million people worldwide.
Asthma patients
Asthma patients are a major customer segment for Innoviva, Inc., with RELVAR/BREO ELLIPTA positioned for long-term respiratory control. The partnership with Glaxo Group Limited covers asthma and COPD, and WHO still estimates asthma affects about 262 million people worldwide, supporting a large recurring-treatment base.
Healthcare professionals
Healthcare professionals, especially pulmonologists and primary care physicians, are the main prescribers for Innoviva, Inc.'s inhaled therapies. Their choices matter in large treatable pools: about 16 million U.S. adults have COPD, and over 25 million Americans have asthma, so each script can directly lift demand.
Payers and formulary managers
Payers and formulary managers are key institutional buyers for Innoviva, Inc. because they decide reimbursement and access, so their approval can directly lift or block product uptake. In U.S. commercial and government coverage, formulary rules shape demand fast, making these decision-makers a core customer segment.
- Reimbursement drives access.
- Formulary approval drives uptake.
Global pharmaceutical partners
Innoviva’s customer segment is mainly global pharmaceutical partners that fund development and commercialize products, so the business works as a B2B royalty and collaboration model. Its latest filings show dependence on external pharma ties, with revenue tied to partner-driven sales rather than direct end customers.
- Global pharma partners drive commercialization.
- External collaboration is core to revenue.
- Direct customers are B2B partners.
Innoviva’s Revenue Hinges on COPD, Asthma, and Pharma Partners
Innoviva, Inc.'s main customer segments are COPD and asthma patients reached through partner-branded inhaled therapies, with prescribing driven by pulmonologists and primary care doctors. The demand pool is large: about 16 million diagnosed U.S. COPD adults, 25 million U.S. asthma patients, and roughly 392 million people living with COPD worldwide.
It also depends on global pharma partners and payers, since Innoviva’s value comes from partner sales, reimbursement, and formulary access rather than direct retail demand. That makes commercialization partners a core B2B customer segment, with access decisions shaping revenue flow.
| Segment | Key number | Why it matters |
|---|---|---|
| COPD patients | 16M U.S.; 392M global | Main therapy base |
| Asthma patients | 25M U.S.; 262M global | Recurring inhaler use |
| Pharma partners | Royalty-led model | Drive sales and revenue |
Cost Structure
Research and development costs
Research and development is a core cost for respiratory drugs, covering formulation, inhalation-device work, and clinical testing. In Innoviva, Inc.’s model, these spend areas stay tied to product development cycles and can move sharply by program; sector R&D intensity often runs above 15% of sales, making it a key margin driver.
Clinical and regulatory costs
Clinical and regulatory costs are a real cash drain for Innoviva, Inc., because trials, FDA submissions, post-market studies, and quality-system compliance are mandatory before respiratory products can reach patients. In FY2025, FDA drug user fee rates and filing steps still add direct expense, but these spend lines are also the gate to market access and revenue.
Commercialization and marketing costs
Commercialization and marketing costs stay partner-led at Innoviva, Inc., but global promotion and field support still matter for brand reach and market access. Once-daily inhalers like Trelegy drive high-value demand, with 2024 global sales around $3.6 billion, so even a royalty model depends on strong launch support and broad physician uptake.
Manufacturing and supply costs
Inhaled combination therapies need exact formulation, sterile filling, device assembly, and cold-chain or controlled distribution, so manufacturing and supply costs stay high. For Innoviva, Inc., pharma-grade quality control, batch release testing, and supply-chain oversight are key cost drivers because even small defects can trigger recalls or lost inventory.
- Complex inhaler production raises unit cost
- Distribution adds logistics and inventory cost
- Quality checks protect against batch failure
General and administrative costs
Innoviva, Inc. carries general and administrative costs to fund management, finance, legal, and alliance administration, and its Burlingame headquarters anchors those functions. This is a recurring overhead line, so it stays in the cost base even when revenue swings.
- Funds core corporate oversight
- Supports alliance administration work
- Runs from Burlingame headquarters
- Stays a continuing cost category
Innoviva’s Cost Base Still Runs Heavy
Innoviva, Inc.’s cost base is still driven by R&D, regulatory work, and supply-chain oversight, while commercialization is mostly partner-led. In FY2025, total operating expenses were $193.7 million, showing that corporate overhead and program spend remain material even in a royalty model.
| Cost item | FY2025 |
|---|---|
| Operating expenses | $193.7M |
| Model impact | R&D, compliance, G&A |
Revenue Streams
Product-related royalties
Innoviva, Inc. earns product-related royalties from partner sales of RELVAR/BREO, ANORO, and TRELEGY, so its top line rises with branded respiratory volumes. This is a classic pharma collaboration stream: in 2025, the model still centered on royalty cash flows from these products, reinforcing Innoviva, Inc.'s asset-light, partner-based structure.
Collaboration payments
Collaboration payments from Glaxo Group Limited remain a core revenue stream for Innoviva, Inc., with income tied to development and commercialization fees under the partnership. In FY2025, this kind of contract-based cash flow stayed central to Innoviva, Inc.'s business model, helping convert licensed respiratory assets into recurring partner-driven revenue.
Milestone payments
Innoviva, Inc. uses milestone payments as a lumpy but visible revenue stream: pharma partners pay when they hit preset development or commercial events, so cash can arrive at trial success, approval, launch, or sales targets. In fiscal 2025, this kind of receipt stayed tied to partner progress, and it helps add upside without needing steady unit sales.
License and commercialization fees
Innoviva, Inc. can earn license and commercialization fees when partners pay for rights to develop, market, or sell products under its agreements. This revenue stream fits its contract-led model, where cash comes from licensing terms and product access, not direct manufacturing.
- Partner-paid license fees
- Commercialization rights income
- Contract-based, not product-led
Strategic alliance income
Innoviva, Inc. uses strategic alliance income as a non-operating revenue stream, and the Sarissa Capital Management LP partnership supports its broader capital-allocation strategy. The economics of this kind of alliance can move reported results, so even small changes in fee share, milestone terms, or governance rights can affect financial outcomes.
- Non-operating collaboration income
- Sarissa supports strategy execution
- Alliance terms can shift earnings
Innoviva’s FY2025 Revenue Relies on Royalties, Collaboration, and Milestones
Innoviva, Inc.'s FY2025 revenue stayed tied to 3 main streams: royalties from RELVAR/BREO, ANORO, and TRELEGY; collaboration income from Glaxo Group Limited; and milestone or license fees that arrive when partners hit set events. It remains a partner-led, asset-light model, not a direct sales model.
| Stream | FY2025 driver |
|---|---|
| Royalties | 3 respiratory brands |
| Collaboration income | Glaxo Group Limited |
| Milestones and fees | Event-based cash |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.